China approves Biogen's CD38 antibody felzartamab for multiple myeloma, its first approval anywhere, months after a $100M TJ Biopharma deal.
Biogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma.
Felzartamab will be available in China for second-line multiple myeloma patients …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
China grants first global approval for felzartamab
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)
Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
FDA Approves First CELMoD Drug for Multiple Myeloma
